What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings?

Pharvaris (NASDAQ:PHVS) – Leerink Partnrs decreased their Q1 2025 earnings per share estimates for Pharvaris in a report released on Monday, April 7th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.91) per share for the quarter, down from their previous estimate of ($0.74). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.63) EPS and FY2026 earnings at ($3.39) EPS.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.06.

Separately, JMP Securities raised their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Trading Up 0.8 %

PHVS opened at $12.00 on Thursday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The firm has a market capitalization of $627.48 million, a PE ratio of -4.29 and a beta of -2.84. The firm’s 50-day moving average price is $15.55 and its 200 day moving average price is $18.36.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Legal & General Group Plc boosted its position in shares of Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock valued at $189,000 after acquiring an additional 994 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock valued at $735,000 after purchasing an additional 1,356 shares during the last quarter. Deutsche Bank AG boosted its holdings in Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock valued at $348,000 after purchasing an additional 2,087 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after buying an additional 2,847 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $57,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.